Concepedia

Anthony Letai

AL

Statistics

Publications

158

Citations

34.7K

H-Index

77

Active since

1988

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Brigham and Women's Hospital

Broad Institute

The University of Texas MD Anderson Cancer Center

Anthony Letai is an author at Dana-Farber Cancer Institute specializing in oncology, molecular oncology, and medicine.

Publications per year

1988–2025

158

Publications

158

The landscape of somatic copy-number alteration across human cancers

Rameen Beroukhim, Craig H. Mermel, Dale Porter et al. · Nature · 2010 · 4.1K citations · Full text

Medicine, Genetics, Molecular Genetics +14

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations

Medicine, Molecular Biology, Oncology +14

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat et al. · New England Journal of Medicine · 2020 · 2.8K citations · Full text

Medicine, Pharmacotherapy, Medical Oncology +3

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat et al. · Blood · 2018 · 1.9K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

Anthony Letai, Michael C. Bassik, Loren D. Walensky et al. · Cancer Cell · 2002 · 1.6K citations · Full text

Life Sciences, Cancer Biology, Oncology +16

1–5 of 158